143 people treated for tick-borne encephalitis (TBE) were included in a retrospective follow-up study. Sequelae and epidemiological characteristics in 114 individuals were analysed. The case fatality rate and the prevalence of residual paresis were low, 1.4 and 2.7%, respectively. However, 40 (35.7%) individuals were found to have a postencephalitic syndrome after a median follow-up time of 47 months, and a majority (77.5%) of these were classified as moderate to severe. Various mental disorders, balance and co-ordination disorders and headache were the most frequently reported symptoms. Increasing age was correlated to a longer duration of hospital stay, longer convalescence and increased risk of permanent sequelae. Results from a neuropsychiatric questionnaire showed marked differences between the subjects with sequelae compared to controls. 57% had noticed a tick bite before admission, and 48% were aware of at least one person in their environment who previously had contracted TBE. 79% were permanent residents or visited endemic areas often and regularly. In conclusion, we have found that TBE in the Stockholm area has a low case fatality rate, but gives rise to a considerable number of different neurological and mental sequelae, which justifies vaccination of a defined risk population in endemic areas.
In 1994 the first human parvovirus B19 (B19) epidemic to be documented in Denmark was recorded from February 2 to September 30. In total, 10,333 serum samples were tested for specific B19 IgM and IgG antibodies, using IDEIA Parvovirus B19 IgM and IgG kits. The prevalence of B19 IgM positivity was 11% for the whole period and 29% at the peak of the epidemic in week 14, declining from week 39 and onwards to 1-3%. The prevalence of B19 IgG (IgM-negative samples) was 60%, indicating an earlier infection, and the same for men and women. The gender distribution of tested patients was the same at the beginning of the epidemic as at the end of the epidemic and a year after its peak, i.e. 86% of samples were from women and only 14% from men. Age distribution for women was the same for the three periods (median age 34 years). For men the median age was 32 years, 39 years and 31 years, respectively. Only a few samples from children were tested. No change in test pattern was observed during the three periods. Approximately 75% of all samples tested were from women of childbearing age (18-45 years old), suggesting a fear of fetal complications in an actual or future pregnancy, rather than a serological verification of clinical symptoms. From the sparse clinical information that accompanied the serum sample we were not able to demonstrate that women were more likely than men to have a symptomatic B19 infection. With reservations we estimate that 14% of adverse pregnancy outcome is correlated with a B19 infection.
The recently discovered human parvovirus 4 (PARV4) is found most frequently in injection drug users, HIV-positive patients, and in haemophiliacs. Studies from Ghana report the finding of PARV4 in plasma from 2 to 12% of children without acute infection, and in nasal secretions and faecal samples. Studies of PARV4 in children from industrialized countries are few.
We aimed to describe the occurrence of PARV4 in a population-based birth cohort of 228 Danish mothers and their healthy children who previously participated in a study of respiratory tract infections in infancy.
Children were included over a whole calendar year and were monitored through monthly home visits through the first year of life. Plasma samples for the present study were available from 228 mothers, 176 newborns, and 202 12-months-old children. All samples were analysed for the presence of PARV4 antibodies by enzyme immunoassay, and samples with detectable antibodies were in addition studied by real-time PCR.
One (0.4%) of 228 mothers had PARV4 IgG exceeding the cut-off absorbance level and another had borderline IgG reactivity. No mother among these two had an acute infection, as they were IgM and PARV4 DNA negative. All blood samples from newborns and one-year-old children had IgG and IgM reactivity below cut-off.
PARV4 is rare in Danish mothers and infants. Further studies are needed, in both rural and urban settings, to investigate the epidemiology and clinical significance of this novel human parvovirus.
The paper gives information on the first case of Crimean-Congo hemorrhagic fever detected in a female resident of the Anapa District, Krasnodar Territory, in 2005 in the past 57 years.
Accelerated decline in Helicobacter pylori seroprevalence rate during the screen and treat project in Vammala, Finland, as demonstrated in 29- to 45-year-old pregnant women.
The potential preventability of serious helicobacter-associated diseases - especially gastric cancer - has evoked interest in eradicating this pathogen from the population. We assessed the efficacy of the pioneering screen and treat intervention project in Vammala by studying helicobacter seroprevalence in pregnant women representing the normal population. Consecutive maternity clinic samples from native Finnish females at five different localities in 1995 (n=701) and 2000 (n=772) were investigated for class IgG H. pylori antibodies by enzyme immunoassay (Pyloriset EIA-G III, Orion Diagnostica, Espoo, Finland). In Vammala the change in helicobacter seroprevalence was -13%-units (between 1995 and 2000; p=0.0125, chi-square test) in > or =29-year-old females, +1.6%-units (difference statistically non-significant) in
The majority of herpes simplex virus type 2 (HSV-2) genital infections are asymptomatic. We wanted to evaluate the acceptance of HSV-2 antibody testing among people attending an STD clinic and to estimate, after counselling, the percentage of recognized and unrecognized HSV-2 infections. First visitors to an STD clinic were invited to participate by answering a questionnaire and taking a blood test for HSV-2 antibodies. HSV-2 seropositive individuals, who were unaware of having genital herpes, were offered an HSV-2 counselling visit and follow-up. Of 1769 patients offered testing, 57% accepted. Of 152 (15%) HSV-2 seropositive individuals, 41% had a self-reported history of genital herpes, approximately 30% had genital symptoms and 30% had no genital symptoms. The percentage of patients reporting genital symptoms was much higher in HSV-2 seropositives (45%) without a history of genital herpes than in an HSV-2 seronegative group (28%). HSV-2 antibody testing should be performed generously in all cases of uncharacteristic genital symptoms.
The aim of this study was to estimate the prevalence of serum antibodies to Actinobacillus pleuropneumoniae (APP) in Finnish farmed wild boars and to evaluate basic risk factors for seropositivity of the agent. A sampling frame was compiled based on the national record of wild boar farmers (n = 117), and 26 herds were included in the study. Serum samples (n = 206) were obtained from all animals slaughtered from these herds during the 2007-2008 period. Indirect enzyme-linked immunosorbent assay techniques were used to detect the possible presence of antibodies toward 12 serotypes of APP. Altogether, 1,442 analyses were performed, out of which 35 (2.4%) exceeded the positive cut-off value. Correspondingly, 26 of the pigs (12.6%) were found to be seropositive for any serotype of APP. The apparent animal prevalence of the cross-reacting APP serotypes 1, 9, and 11 was 3.9% (95% confidence interval [CI] 1-7%); it was 0.5% (CI 0-1%) for serotype 2; 3.4% (CI 1-6%) for serotypes 3, 6, and 8; 7.3% (CI 4-11%) for serotypes 4 and 7; 0.5% (CI 0-1%) for serotype 10; and 1.5% (CI 0-3%) for serotype 12. No antibodies against serotype 5s were detected. The apparent farm prevalence of APP serotypes 1,9, and 11 was 15.4% (CI 2-29%); that of serotype 2 was 3.8% (CI 0-11%); that of serotypes 3, 6, and 8 was 11.5% (CI 0-24%); that of serotypes 4 and 7 was 34.6% (CI 16-53%); that of serotype 10 was 3.8% (CI 0-11%); and that of serotype 12 was 7.7% (CI 0-18%). In conclusion, the prevalence of serum antibodies to different APP serotypes was low in farmed wild boar. Risk factor analysis did not reveal any significant animal- or herd-level risk factors for seropositivity of the agent.
Inkoo virus (INKV) and Chatanga virus (CHATV), which are circulating in Finland, are mosquitoborne California serogroup orthobunyaviruses that have a high seroprevalence among humans. Worldwide, INKV infection has been poorly described, and CHATV infection has been unknown. Using serum samples collected in Finland from 7,961 patients suspected of having viral neurologic disease or Puumala virus infection during the summers of 2001-2013, we analyzed the samples to detect California serogroup infections. IgM seropositivity revealed 17 acute infections, and cross-neutralization tests confirmed presence of INKV or CHATV infections. All children (
Notes
Cites: N Engl J Med. 2001 Mar 15;344(11):801-711248155
Cites: MMWR Morb Mortal Wkly Rep. 2011 May 27;60(20):652-521617630
Cites: Am J Trop Med Hyg. 1973 May;22(3):404-134145218
Cites: Am J Trop Med Hyg. 1973 Sep;22(5):654-614729744
Cites: Pediatrics. 1973 Nov;52(5):680-914355363
Cites: Acta Virol. 1975 Sep;19(5):447241253
Cites: Acta Pathol Microbiol Scand B. 1978 Dec;86B(6):335-4131761
Cites: Can Med Assoc J. 1980 Jan 12;122(1):60-2, 647363197
Cites: Am J Trop Med Hyg. 1982 Nov;31(6):1238-447149109
Cites: J Hyg (Lond). 1985 Feb;94(1):111-222857742
Cites: Am J Trop Med Hyg. 1989 Sep;41(3):355-632572178
Cites: Am J Trop Med Hyg. 1991 Sep;45(3):366-701928572
Cites: Am J Trop Med Hyg. 1991 Sep;45(3):371-61928573
Antibody cross-reactivity to the influenza A(H3N2) variant virus recently reported in the United States, was investigated in Norwegian sera. Seroprevalence was 40% overall, and 71% in people born between 1977 and 1993. The most susceptible age groups were children and people aged around 50 years. The high immunity in young adults is likely to be due to strong priming infection with similar viruses in the 1990s. More research is needed to explain the poor immunity in 45?54 year-olds.
